Human TL1A/TNFSF15 (hTL1A) #11946
Inquiry Info. # 11946
Please see our recommended alternatives.
Product Information
Formulation
With carrier: Lyophilized from a 0.22 μm filtered solution of hTL1A in 20 mM Tris, pH 7.2 containing 20 μg BSA per 1 μg hTL1A. Carrier free: Lyophilized from a 0.22 μm filtered solution of hTL1A in 20 mM Tris, pH 7.2.
Storage
Stable in lyophilized state at 4°C for 1 year after receipt. Sterile stock solutions reconstituted with carrier protein are stable at 4°C for 2 months and at -20°C for 6 months. Avoid repeated freeze-thaw cycles. Maintain sterility. Storage at -20°C should be in a manual defrost freezer.
Product Description
MW (kDa) | 21 |
Purity | >95% as determined by SDS-PAGE of 6 μg reduced (+) and nonreduced (-) recombinant hTL1A. All lots are greater than 95% pure. |
Endotoxin | Less than 0.01 ng endotoxin/1 μg hTL1A. |
Activity | The bioactivity of hTL1A was determined in a TF-1 cell viability assay. The ED50 of each lot is between 2-15 ng/ml. |
Molecular Formula | Recombinant hTL1A has a calculated MW of 20,0473. DTT-reduced protein migrates as a 21 kDa polypeptide. The nonreduced protein migrates as a 21 kDa monomer and 38 kDa cystine-linked homodimer. The expected amino terminus of recombinant hTL1A was verified by amino acid sequencing. |
Source / Purification
Recombinant Human TL1A Leu72-Leu251 (Accession #NP_095150) was expressed in E.coli at Cell Signaling Technology.
Background
TL1A (TNFSF15), a member of the TNF superfamily of proteins, is a splice variant of the TL1/VEGI gene (1). Endothelial cells, monocytes, macrophages, and dendritic cells express TL1A, which is upregulated by proinflammatory cytokines, microorganisms, and AMPK activation (1-4). TL1A activates the NF-κB and JNK pathways through its receptor, DR3 (1,5). TL1A may function as a costimulatory signal for T cell activation, specifically regulating Th17 cell development and proliferation (1,2,6). Mouse models suggest a role for TL1A as a driver for the inflammation and pathogenesis associated with inflammatory bowel disease (7,8).
- Migone, T.S. et al. (2002) Immunity 16, 479-92.
- Jones, G.W. et al. (2011) FASEB J 25, 409-19.
- Zhou, J. et al. (2011) Oncogene 30, 1892-900.
- Shih, D.Q. et al. (2009) Eur J Immunol 39, 3239-50.
- Haridas, V. et al. (1999) Oncogene 18, 6496-504.
- Pappu, B.P. et al. (2008) J Exp Med 205, 1049-62.
- Meylan, F. et al. (2011) Mucosal Immunol 4, 172-85.
- Taraban, V.Y. et al. (2011) Mucosal Immunol 4, 186-96.
限制使用
除非 CST 的合法授书代表以书面形式书行明确同意,否书以下条款适用于 CST、其关书方或分书商提供的书品。 任何书充本条款或与本条款不同的客书条款和条件,除非书 CST 的合法授书代表以书面形式书独接受, 否书均被拒书,并且无效。
专品专有“专供研究使用”的专专或专似的专专声明, 且未专得美国食品和专品管理局或其他外国或国内专管机专专专任何用途的批准、准专或专可。客专不得将任何专品用于任何专断或治专目的, 或以任何不符合专专声明的方式使用专品。CST 专售或专可的专品提供专作专最专用专的客专,且专用于研专用途。将专品用于专断、专防或治专目的, 或专专售(专独或作专专成)或其他商专目的而专专专品,均需要 CST 的专独专可。客专:(a) 不得专独或与其他材料专合向任何第三方出售、专可、 出借、捐专或以其他方式专专或提供任何专品,或使用专品制造任何商专专品,(b) 不得复制、修改、逆向工程、反专专、 反专专专品或以其他方式专专专专专品的基专专专或技专,或使用专品开专任何与 CST 的专品或服专专争的专品或服专, (c) 不得更改或专除专品上的任何商专、商品名称、徽专、专利或版专声明或专专,(d) 只能根据 CST 的专品专售条款和任何适用文档使用专品, (e) 专遵守客专与专品一起使用的任何第三方专品或服专的任何专可、服专条款或专似专专
For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
All other trademarks are the property of their respective owners. Visit our
Trademark Information page.